A social networking community for Christian friends - share ideas - meet single christians - ChristianVibes.com

News: Self-Recovery; New Drug; Stigma; Vaccine; Alinia

This Research and Treatment News update gives you highlights from the latest articles posted to Hepatitis-Central.com for patients and their families, caregivers and health professionals. With new information being published regularly, we want you to have the latest news on treatments, clinical trials, social issues and important breakthroughs as soon as it becomes available.

Please note: Our email address will be changing soon, so you'll want to whitelist our new sending address: editors@email.hepatitis-central.com. For more details, click here.

Factors Influencing Self-Recovery from Hepatitis C

As reported in the August 21, 2007 edition of the World Journal of Gastroenterology, researchers investigated why some people are able to spontaneously recover from the Hepatitis C virus. This study found the following factors responsible for a person’s ability, or inability, to self-recover from the virus – quantity of Hepatitis C antibody, co-infection with Hepatitis B, and the active use of IV drugs.

To learn more, click here.

Clinical Trial, New Drug for Hepatitis C Viral Infection

Learn about Implicit Bioscience’s drug, Oglufanide Disodium, now in a Phase IIa clinical trial to test its ability for overpowering Hepatitis C.

To learn more, click here.

Breaking the Hepatitis C Social Stigma

More people are currently living with Hepatitis C than any other chronic blood-borne infectious disease. Many patients still suffer with the associated stigma in many social circles. Discover two ways to reduce this unfortunate perception of a Hepatitis C diagnosis. Your efforts can help make the changes required.

To learn more, click here.

Future HCV Medication and Vaccine from Japan

Using inactivated Hepatitis C particles, a Japanese company has successfully suppressed the Hepatitis C virus in mice. This scientific development holds enormous potential as a Hepatitis C vaccine and possibly as a therapeutic medication for those already infected.

To learn more, click here.

Alinia Tablets and Hepatitis C

For HCV genotype 1 patients who have failed to respond to standard therapy (peginterferon and ribavirin), Romark Laboratories has designed a clinical trial to test the safety and effectiveness of Alinia (nitazoxanide). Learn more about the Phase II clinical trial during which nitazoxanide tablets are administered in combination with Pegasys and Copegus, in 60 patients with the most common genotype in North America.

To learn more, click here.

To learn even more, visit Hepatitis-Central.com, where you'll find more than 2,750 pages of in-depth information for HCV patients and their families, caregivers and health professionals. In case you missed a recent Hep-Cen Update, or would like to search through any of the archived, in-depth news and commentary pages, visit the Hepatitis C Information Center at Hepatitis-Central.com.

Note: LiverSupport Health News, our other newsletter, gives you valuable lifestyle suggestions and news-you-can-use, from our LiverSupport.com editors. Just click here to sign up for LiverSupport Health News, and learn even more about supporting liver health for you and your family.


Yours in health,

Editors at Hepatitis-Central.com
www.Hepatitis-Central.com
editors@Hepatitis-Central.com
1-800-364-5722

*** HEPATITIS C PATIENTS recommend Ultra Thistle. Learn why. ***